about
High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s diseaseMicrobial-gut interactions in health and disease. Antibiotic-associated diarrhoeaPredictive factors of response to cyclosporine in steroid-refractory ulcerative colitis.Rotavirus-like particles: a novel nanocarrier for the gut.Prior appendectomy and the phenotype and course of Crohn's diseasePregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study.Bacterial protein signals are associated with Crohn's disease.Genotype/phenotype analyses for 53 Crohn's disease associated genetic polymorphisms.Fungal microbiota dysbiosis in IBD.Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohn's Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis.Factors affecting outcomes in Crohn's disease over 15 years.Clinical, serological and genetic predictors of inflammatory bowel disease course.Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum.Azathioprine induction of tumors with microsatellite instability: risk evaluation using a mouse model.Cancer risk in immune-mediated inflammatory diseases (IMID).Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis.CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands.Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases.Gastrointestinal involvement and manifestations in systemic mastocytosis.The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis.Inflammatory bowel disease therapies and cancer risk: where are we and where are we going?Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease.Immunosuppression-related lymphomas and cancers in IBD: how can they be prevented?Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations.Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process.The management of immunosuppression in patients with inflammatory bowel disease and cancer.Use of immunosuppressants and biologicals in patients with previous cancer.Management of inflammatory bowel disease patients with a cancer history.Cancers complicating inflammatory bowel disease.European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies.Anal Neoplasia in Inflammatory Bowel Disease: Classification Proposal, Epidemiology, Carcinogenesis, and Risk Management Perspectives.Patient-reported Outcomes in a French Nationwide Survey of Inflammatory Bowel Disease Patients.Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy.Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study.Erythema nodosum-like eruption as a manifestation of azathioprine hypersensitivity in patients with inflammatory bowel disease.Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective Study.Detection of Dysplasia or Cancer in 3.5% of Patients With Inflammatory Bowel Disease and Colonic Strictures.Faecal microbiota transplantation in recurrent Clostridium difficile infection: Recommendations from the French Group of Faecal microbiota Transplantation.[Non-digestive complications of inflammatory bowel diseases].Factors associated with durable response to infliximab in Crohn's disease 5 years and beyond: a multicenter international cohort.
P50
Q22250942-1EC3EA1B-2C6A-4038-8C12-CBAE79170CD8Q28259833-22080287-ED18-4308-8E24-2CC37CAC5513Q33307776-972F8690-B9E5-45E9-BF61-4D6C1B3D1D09Q33794939-3496A7DF-E644-44D4-B600-B1AA824954B7Q34013172-FDC31F54-9CF7-4195-BCBC-5D21B2C6268AQ34152305-8A0E8443-DBFC-4649-9AA5-083887750105Q34237245-6EA7868C-16E5-49B3-BF0A-9B833D2C5539Q34540483-A9E1DCEB-D7E9-4DF7-8BA1-E352FCBDED6BQ35914203-8F0471EE-C265-4E35-B232-2DC00C50F8CDQ36043446-75775B25-34EE-4FA0-976E-0872A7D4CFA4Q36073254-8BE72FE9-2843-4EF2-A587-8230D0735961Q36144470-2F9E7332-FAB6-40CF-A72F-AF2890E4A4D1Q36204640-C67BC111-85A4-43C5-BD48-195A726B187BQ36413082-7990D857-BDE2-4878-A1D6-7F9E5D06B4EDQ37153407-3DB940AF-34ED-4F8F-BB31-55680DBE3F98Q37277424-C4693423-2BC8-475C-9EB1-B3B2A0AF2AE6Q37380370-05FD8445-B3ED-4F9E-8E34-E46AC6FB9B44Q37656035-A374A8D6-C850-4595-8DC5-274144A6E610Q37693842-DE0105C9-D45B-4DF7-899D-C411F3F8B003Q37814539-D9020554-02DF-4D39-BF8B-C4834437065EQ37966926-D4638130-6074-47F6-B7C8-9989D20A6DD3Q37978252-1F2BFE41-63CA-424D-A84C-23668CC50F9FQ38026406-5BBCB5CF-48AE-4216-8159-7EDCDE3F48C7Q38049779-A72AF5EB-F5DD-4841-B4BB-20E085273281Q38065036-646B7A37-6059-4F4C-9C15-B055D88FB66DQ38125570-26794ACD-657F-40F5-AFA9-C9E66697EA89Q38136964-789DA74E-331D-4C54-A711-DDF679A098F7Q38242105-4FE4A5AB-AADA-4BD4-A3D6-A6423F81FB58Q38411599-93A0F05B-27B9-4FDD-9740-0E8EDA7FC412Q38570841-562FB9B5-5F98-46B6-B4DF-3790D271072EQ39221586-29942BA6-0E90-434A-860A-9FA58ECC20F8Q39497018-EF84783F-9AC7-4050-9FDD-E7FCCDAB687CQ39965627-07C7CFCC-8C3E-4604-B37A-AE8057AB43AAQ40146700-9AC15BC4-851D-4D1C-B52C-7D4F3BFCE784Q40446863-29324B7A-6065-47EF-809F-17CC9658C536Q40560538-42B99DCF-9148-4C05-B6D1-D4D001998D46Q40911082-1348A650-8FB0-4410-A4ED-E4A735F58860Q40967606-3BCC15E1-B0E7-423D-AA90-4BB2C846D65AQ41511597-093AD5BD-B46A-4725-9BAD-10BD4B1B6F1CQ41679019-78580F9A-7046-4113-B630-082FCE2185B6
P50
name
Laurent Beaugerie
@en
Laurent Beaugerie
@nl
type
label
Laurent Beaugerie
@en
Laurent Beaugerie
@nl
prefLabel
Laurent Beaugerie
@en
Laurent Beaugerie
@nl